Compare Medications

Foundayo and Wegovy are both GLP-1 medications approved for weight loss, but they work differently, cost differently, and fit different lifestyles. Foundayo (orforglipron) is Eli Lilly's new daily pill — no food restrictions, no injections. Wegovy (semaglutide) is available as a weekly injection or daily pill (with fasting requirements). Here's how they compare on everything that matters.

Foundayo and Zepbound are both Eli Lilly products, but they serve different purposes in your weight loss journey. Lilly has explicitly positioned them as complementary: 'Use Zepbound to lose, switch to Foundayo to maintain.' But is that the right strategy for everyone? Let's compare.

Ozempic has been the dominant GLP-1 for years. Now Foundayo enters as a cheaper, oral alternative. Ozempic is FDA-approved for diabetes (widely used off-label for weight loss), while Foundayo is approved specifically for weight management. Here's the full comparison.

Both Foundayo and Rybelsus are oral GLP-1 medications, but the comparison is almost unfair. Foundayo is a newer, more convenient pill with no food restrictions. Rybelsus was the first oral GLP-1 (2019) but has strict fasting requirements and is approved for diabetes, not weight loss. Here's how they stack up.

For the first time, patients choosing a GLP-1 for weight loss can pick between two oral options — no injections required. Foundayo (orforglipron) and the Wegovy pill (oral semaglutide 50mg) both arrived in the last six months, but they're built on fundamentally different technology. One is a small molecule you can take any time; the other is a peptide that demands a strict fasting routine. Here's how they compare on everything that matters.

Zepbound and Wegovy are the two most prescribed injectable weight loss medications in the world. Now we have a direct head-to-head trial — SURMOUNT-5 — which showed tirzepatide producing significantly more weight loss than semaglutide. But Wegovy has cardiovascular outcomes data that Zepbound lacks. Here's the full picture.

Same molecule, same company, radically different experience. Since December 2025, Wegovy is available as both a daily pill and a weekly injection. The pill eliminates needles and costs a fraction of the price — but it comes with a strict fasting requirement and uses a 50mg dose to compensate for ~1% oral bioavailability. Here's what you need to know to choose between them.

Here's the simplest comparison on this site: Zepbound and Mounjaro are the exact same drug. Same molecule (tirzepatide), same manufacturer (Eli Lilly), same injection pen. The only differences are the FDA-approved indication, the label, and — critically — how insurance covers them. This page exists because thousands of people search for this comparison every month, and the distinction matters for your wallet.

Millions of Americans turned to compounded semaglutide when Wegovy and Ozempic were in shortage and unaffordable. Now the landscape has changed: Foundayo costs $149–349/month, FDA shortages have resolved, and the FDA is cracking down on compounders. If you're on compounded semaglutide — or considering it — here's why switching to an FDA-approved option like Foundayo makes sense.

Two heavyweight GLP-1 combinations go head-to-head. CagriSema combines amylin + GLP-1 for 22.7% weight loss. Zepbound uses dual GIP + GLP-1 for 22.5%. They're nearly identical on efficacy — so the decision comes down to availability, cardiovascular data, and cost.

Both are Lilly drugs, but retatrutide adds a third receptor — glucagon. The result? 28.7% weight loss in Phase 2, the highest ever recorded. But it's still in Phase 3. Here's how it compares to the already-available Zepbound.

Both are Novo Nordisk products. Wegovy is semaglutide alone (15% weight loss). CagriSema adds cagrilintide (amylin analog) to semaglutide for 22.7%. That's 50% more weight loss from the same company. But Wegovy is available now, and CagriSema won't launch until 2027.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly injectable medications approved for type 2 diabetes — but they're increasingly compared for weight loss, too. Ozempic is a GLP-1 receptor agonist approved since December 2017 with proven cardiovascular benefits and an oral option (Rybelsus). Mounjaro is a dual GLP-1/GIP receptor agonist approved in May 2022 that produces stronger weight loss and A1C reduction. Here's how they stack up across every metric that matters.

Wegovy (semaglutide 2.4mg) was approved in June 2021 specifically for weight management and has become the most recognized GLP-1 weight loss drug. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes but widely used off-label for weight loss — Zepbound is the FDA-approved weight loss brand of the same molecule. Both produce dramatic weight loss, but they differ in mechanism, cost, FDA indication, and cardiovascular evidence.

Vyvanse and Concerta are two of the most widely prescribed ADHD medications in the U.S., offering extended-release formulations for sustained symptom control. While both are effective for managing inattention, hyperactivity, and impulsivity, they differ significantly in drug class, mechanism, and pharmacokinetics. Vyvanse is an amphetamine-based prodrug that converts to dextroamphetamine in the body, while Concerta uses methylphenidate delivered via Janssen's OROS (osmotic-controlled release oral delivery system). This fundamental difference influences onset, duration, and abuse potential.

For patients who cannot tolerate stimulants or prefer non-stimulant options, Strattera and Qelbree offer effective alternatives for managing ADHD. Both are non-scheduled medications with no abuse potential, but they differ meaningfully in mechanism, onset of action, and side effect profiles. Strattera (atomoxetine), approved in 2002, is a selective norepinephrine reuptake inhibitor. Qelbree (viloxazine ER), approved in 2021, modulates both norepinephrine and serotonin pathways. Understanding these differences can help patients and clinicians choose the best non-stimulant option.

Yaz and Beyaz are both combination oral contraceptives made by Bayer with nearly identical hormonal formulations. Both contain drospirenone 3mg and ethinyl estradiol 20mcg in a 24/4 regimen (24 active pills followed by 4 inactive pills). The key difference: Beyaz adds levomefolate calcium 0.451mg, a form of folic acid that helps build folate stores to reduce the risk of neural tube defects if pregnancy occurs. Both are FDA-approved for contraception, moderate acne, and PMDD. The choice between them typically comes down to reproductive planning and cost.

Mirena and Kyleena are both T-shaped hormonal intrauterine devices (IUDs) made by Bayer that release levonorgestrel directly into the uterus. Both are FDA-approved for up to 5 years of contraception with over 99% efficacy. The key differences lie in hormone dose, device size, and clinical applications. Mirena delivers a higher dose (52mg total) and is also approved for treating heavy menstrual bleeding. Kyleena has a lower dose (19.5mg total), a slightly smaller frame, and may produce fewer systemic hormonal side effects while allowing most women to keep lighter periods.

Nurtec ODT and Qulipta are both oral calcitonin gene-related peptide (CGRP) receptor antagonists—a class of migraine medications called "gepants." They represent a major advance over older preventives because they target the CGRP pathway specifically involved in migraine pathophysiology, with fewer systemic side effects than traditional options like beta-blockers or topiramate. The key distinction: Nurtec is FDA-approved for both acute treatment and prevention (dual indication), while Qulipta is approved for prevention only. This comparison explores which one may be right for you.

Aimovig and Emgality are both injectable monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway for migraine prevention. They represent a transformative class of preventive treatments that are more targeted and generally better tolerated than older options like topiramate, amitriptyline, or beta-blockers. The key mechanistic difference: Aimovig blocks the CGRP receptor, while Emgality binds and neutralizes the CGRP ligand (protein) itself. Emgality also holds an additional FDA approval for episodic cluster headache. Both are given as monthly self-injections.